Phase 1b/2a trial expected to commence in Q3 2023 First readout anticipated in 2024 VANCOUVER, BC — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF)(“NervGen” or the “Company”), a clinical stage biotech company… Read More
VANCOUVER, BC — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster… Read More
Vancouver, BC — Genome British Columbia (Genome BC) has announced $1M in funding to support four unique projects aimed at enabling discoveries to address unmet clinical healthcare needs through its Data… Read More
SOUTH SAN FRANCISCO, CA and VANCOUVER, BC — /CNW/ — ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of… Read More
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to receive 75 million US dollars… Read More
